601 Versus Ranibizumab in Patients With Pathological Myopic Choroidal Neovascularization (pmCNV)

Inclusion Criteria:

• Sign informed consent form and willing to be visited at the time specified in thetrial
• Male or Female, at least 18 years of age
• The study eye must meet the following criteria
• Diagnosed with active choroidal neovascularization secondary to pathological myopia
• BCVA score between 78 and 24 letters, inclusive, using ETDRS visual acuity testingcharts (approximate Snellen equivalent of 20/32 to 20/320)
• No optometric media opacity and pupil abnormal
• BCVA score ≥ 34 letters in the fellow eye, using ETDRS visual acuity testing charts (approximate Snellen equivalent of 20/200)

Exclusion Criteria:

• CNV secondary to other causes (except pathological myopia), such asneovascularage-related macular degeneration (nAMD), polypoid choroidal vasculardisease (PCV), and secondary injury
• The fovea has fibrosis and organochemical foci or scar or atrophy that obviouslyinvolves the fovea and causes irreversible vision loss;
• Previous use of intraocular or periocular steroids within 3 months prior to baseline,or previous use of dexamethasone intravitreal implant within 6 months prior toenrollment;
• PDT, Macular laser photocoagulation (focal/grid), vitrectomy or keratoplasty in thestudy eye at any time prior to baseline. Panretinal laser photocoagulation，YAG lasertreatment or any other ocular surgeries (e.g. cataract surgery ) in the study eyewithin 3 months prior to the baseline
• Aphakia (except IOL) or posterior capsular defect (except YAG posterior capsulotomyafter intraocular lens implantation surgery) For Any Eye:
• Any eye has active ocular infections (e.g. blepharitis, conjunctivitis, keratitis,scleritis, uveitis, endophthalmitis)
• History of intravitreal use of anti-VEGF drugs (e.g.ranibizumab，bevacizumab，aflibercept, conbercept, etc.) in any eye within 3 monthsprior to baseline General Exclusion Criteria:
• History of allergy to fluorescein sodium and allergies to protein products fortreatment or diagnosis
• History of stroke (cerebrovascular accident), myocardial infarction, activedisseminated intravascular coagulation or pronounced bleeding tendency in the past 6months prior to baseline
• Diagnosed systemic immune diseases (e.g. ankylosing spondylitis, systemic lupuserythematosus, Behcet's disease, rheumatoid arthritis, scleroderma etc.)
• any uncontrolled clinical problem (e.g. AIDS, active hepatitis, serious mental,neurological, cardiovascular, respiratory and other systemic diseases or malignanttumors, etc.). Malignant tumors with no metastasis or recurrence within 5 years orcancers in situ cancers are not excluded.
• History of system use of anti-VEGF drugs (e.g. bevacizumab) within 3 months prior tobaseline Laboratory Exclusion Criteria:
• Liver dysfunction (ALT or AST is 2 times higher than the upper limit of normal valuein the local laboratory). Renal function impairment (Cr is 1.5 times higher than theupper limit of normal values in the local laboratory)
• Abnormal coagulation function (prothrombin time >= the upper limit of normal value for 3 seconds) and activated partial thromboplastin time >= the upper limit of normalvalue for 10 seconds); Other Exclusion Criteria:
• Non-use of effective contraception during childbearing age (except for women withspontaneous admonishment of more than 12 months)
• Pregnancy and lactation women